

#144

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Thursday, September 18, 2025 6:07:50 PM
Last Modified: Thursday, September 18, 2025 6:26:57 PM
Time Spent: 00:19:07
IP Address: 142.198.46.170

Page 2: Part 1

Q1

Title of activity

RAFT Debate

Q2

Date of activity

Saturday Oct 18th 2025

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Academic Practice

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Pfizer, Viatris, OMA, AACI

Description of relationship(s)

Pfizer and Viatris consulting,

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

DBV Technologies, ALK Abello, Food Allergy Canada, NACI, Pharming

Description of relationship(s)

advisory boards

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

DBV Technologies, ALK Abello, Sanofi/Regeneron, RAPT, Aquestive, SKFAAP, CIHR, CITE, Toronto COVID-19 Action Fund, Novartis

Description of relationship(s)

trials for food allergy and vaccine efficacy, Novartis donated drug for trial

Q9

Respondent skipped this question

Patents on a drug, product or device

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s)
(separate with commas)

Associate Editor AACI, editorial boards (Allergy, Annals of Allergy, Asthma & Immunology, Journal of Food Allergy)

Page 3: Part 2: To be completed by presenters only

Q11

No

I intend to use trade names during my presentation. Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

Q12

No

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation.

Q13**N/A**

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

Q14**Yes**

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15**Yes**

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Julia

Q17

Last Name:

Upton

Q18**She/Her**

Gender Pronouns - How would you like us to address you?

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available
